For relapsed or refractory CD30+ PTCL, a phase 2 study reported the efficacy of BV monotherapy [5], establishing BV as a key drug in CD30+ PTCL treatment. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.